top of page
Browse by category
Search
Analysis of SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV events
Analysis of the SCORE and PRIDE studies shows semaglutide results in improved functional outcomes, health-related quality of life and CV...
Expanding access to anti-obesity medications delivers 13% return on investment for society
A USC Schaeffer Center white paper entitled, ‘Lifetime Social Returns From Expanding Access to Anti-Obesity Medication’, finds expanded...
First patient dosed in study of Corbus’ next-generation CB1 Inverse Agonist CRB-913 for the treatment of obesity
The first patient has been dosed in Corbus Pharmaceuticals in the single ascending dose/multiple ascending dose (SAD/MAD) portion of the...
Vivani issues positive preclinical weight loss data for NPM-139 semaglutide implant
Vivani Medical has announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic...
BMS demonstrates superior efficacy over non-surgical treatments in managing obesity and associated metabolic disorders
A systematic review and meta-analysis of randomised clinical trials (RCTs) underscores the superior efficacy of bariatric and metabolic...
Sucralose alters brain activity related to hunger and increases appetite, especially in people with obesity
A study from the Keck School of Medicine of USC found that sucralose, a common sugar substitute, alters brain activity related to hunger...
Browse by tag
bottom of page